Insight into the colonic disposition of celecoxib in humans
- 1 March 2020
- journal article
- research article
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 145, 105242
Abstract
No abstract availableKeywords
Funding Information
- Flanders Innovation & Entrepreneurship (155042)
This publication has 13 references indexed in Scilit:
- Role of Sulindac and Celecoxib in the regulation of angiogenesis during the early neoplasm of colon: Exploring PI3-K/PTEN/Akt pathway to the canonical Wnt/β-catenin signalingBiomedicine & Pharmacotherapy, 2012
- Celecoxib pathwaysPharmacogenetics and Genomics, 2012
- Gastric transit and small intestinal transit time and motility assessed by a magnet tracking systemBMC Gastroenterology, 2011
- Celecoxib for the Prevention of Sporadic Colorectal AdenomasNew England Journal of Medicine, 2006
- Cyclooxygenase-2 (COX-2)–Independent Anticarcinogenic Effects of Selective COX-2 InhibitorsJNCI: Journal of the National Cancer Institute, 2006
- Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imagingAlimentary Pharmacology & Therapeutics, 2005
- Use of NSAIDs for the Chemoprevention of Colorectal CancerAnnals of Pharmacotherapy, 2003
- Investigation of the pharmacokinetics of celecoxib by liquid chromatography–mass spectrometryBiomedical Chromatography, 2001
- Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib)Journal of Medicinal Chemistry, 1997
- Effect of painless rectal distension on gastrointestinal transit of solid mealDigestive Diseases and Sciences, 1984